The Pharma Data

JUNE 19, 2023

The findings bolster the idea, which is currently under investigation in at least three clinical trials, that when it comes to treating resistant breast cancer, two drugs may be better than one.

Drugs 40

Drugs HR Scientist Hormones 40

The Pharma Data

JULY 22, 2021

(NYSE: PFE) today announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. We share Pfizer’s deep commitment to people with breast cancer and are thrilled to partner with them to develop this potentially best-in-class therapy.

Protein 52

Protein Development HR Hormones 52

Drug Discovery World

MARCH 24, 2023

Additionally, the trial design incorporates feedback from Scientific Advice meetings with the European Medicines Agency (EMA) to support a Marketing Authorisation Application (MAA). The Phase III will have overall survival as the primary objective and may include a specific patient population.

Trials 52

Trials Immune Response HR Clinical Development 52

The Pharma Data

JUNE 7, 2023

Rubin, senior vice president, global clinical development, Merck Research Laboratories. Patients with stage III and IV melanoma can be at high risk of having their cancer recur or metastasize to other sites,” said Dr. Eric H. The safety profile of KEYTRUDA was consistent with findings from previous studies.

Clinical Trials 40

Clinical Trials Clinical Trials HR Medicine 40

The Pharma Data

JANUARY 14, 2021

“The FIGHT trial results demonstrate that treatment with bemarituzumab in combination with chemotherapy can deliver a significant reduction in the risk of disease progression and death in gastric cancer patients whose tumors overexpress FGFR2b.”. HR (95% CI): 0.68. HR (95% CI): 0.54 (0.33, 0.87).

Trials 52

Trials HR Containment Development 52

The Pharma Data

MARCH 17, 2022

The study found that adjuvant treatment with KEYTRUDA significantly improved disease-free survival (DFS), one of the dual primary endpoints, reducing the risk of disease recurrence or death by 24% compared to placebo (hazard ratio [HR]=0.76 [95% CI, 0.63-0.91]; 0.91]; p=0.0014) in patients with stage IB (?4

Clinical Trials 52

Clinical Trials Clinical Trials Research Trials 52

The Pharma Data

NOVEMBER 18, 2021

The blessing is grounded on data from the vital Phase 3 KEYNOTE-564 trial, in which KEYTRUDA demonstrated a statistically significant enhancement in complaint-free survival (DFS), reducing the threat of complaint rush or death by 32 (HR = 0.68 (95 CI,0.53-0.87); 0.87); p = 0.0010) compared to placebo. 0.87); p = 0.0010). About Merck.

FDA Approval 52

FDA Approval HR Trials Drugs 52

The Pharma Data

MAY 26, 2023

4,5) The FDA approval of PAXLOVID is based on the totality of scientific evidence shared by Pfizer, including safety and efficacy data from the EPIC (Evaluation of Protease Inhibition for COVID-19) clinical development program. .” COVID-19 continues to cause significant burden in the U.S.

FDA Approval 40

FDA Approval HR Vaccination Vaccine 40

The Pharma Data

DECEMBER 29, 2020

NASDAQ: REGN) today announced encouraging initial data from an ongoing Phase 1/2/3 clinical trial of the Regeneron antibody cocktail, casirivimab and imdevimab, in hospitalized COVID-19 patients requiring low-flow oxygen. Evaluation of its safety and efficacy is ongoing in multiple clinical trials. In the U.S.

Antibody 52

Antibody Trials Production Clinical Trials 52

XTalks

DECEMBER 4, 2020

Recently, Medpace hosted an informative webinar on CKD and how new developments in our understanding of the disease are helping to shape more effective clinical research programs. Watch this free webinar to learn more about CKD from Medpace’s medical and clinical operations experts. Developed in 1999 2.

Trials 52

Trials Clinical Trials Clinical Trials Antibody 52

The Pharma Data

JANUARY 20, 2021

Verquvo met the primary efficacy objective based on a time-to-event analysis (hazard ratio [HR]: 0.90, 95% confidence interval [CI], 0.82-0.98; This approval builds upon Merck’s proud history of developing therapies for the treatment of patients with cardiovascular disease.”. 0.98; p=0.019). Over the course of the study, there was a 4.2%

FDA Approval 52

FDA Approval Production Trials Clinical Trials 52

The Pharma Data

MARCH 17, 2021

The data builds on the primary outcome analysis of the positive Phase 3 monarchE trial that previously showed Verzenio, in combination with ET, decreased the risk of breast cancer recurrence by 28.7 High risk was specifically defined as women (any menopausal status) and men with resected HR+, HER2- invasive early breast cancer with either ?4

HR 52

HR Trials In-Vitro Manufacturing 52

The Pharma Data

AUGUST 30, 2021

“We are pleased to offer two potential new treatment options with KEYTRUDA for patients in Japan based on compelling data from our clinical trial program,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. months (95% CI, 7.6-11.3)

Hormones 52

Hormones HR Trials Protein 52

XTalks

AUGUST 2, 2023

5) Ibrance (palbociclib) Ibrance is a chemotherapy drug indicated for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. Clinical trials have shown that the vaccine is 90 percent effective in preventing shingles for individuals aged 50 and over. billion ($3.65

Sales 98

Sales Manufacturing FDA Approval Life Science 98

Drug Discovery World

OCTOBER 7, 2022

HR : We have some great assets at CRUK – access to world-leading cancer biology, strong, proven drug discovery capabilities and access to a network of life-science organisations – Cancer Research Horizons was set up to expand on these assets and make them accessible to researchers, investors and industry through collaboration. Hamish Ryder.

HR 52

HR Research Drugs Development 52

The Pharma Data

MARCH 31, 2023

months, Opdivo with chemotherapy reduced the risk of disease recurrence, progression or death by 32%, demonstrating a landmark three-year event-free survival (EFS) rate of 57% with Opdivo with chemotherapy compared to 43% with chemotherapy alone (Hazard Ratio [HR], 0.68; 95% Confidence Interval [CI], 0.49 With median follow up of 41.4

Trials 40

Trials HR Medicine Development 40

The Pharma Data

APRIL 16, 2021

Bristol Myers Squibb thanks the patients and investigators involved in the CheckMate -9ER clinical trial. In the CheckMate -9ER trial, Opdivo in combination with Cabometyx showed superior PFS, ORR and OS versus sunitinib, with a low rate of TRAEs leading to discontinuation. months, respectively; HR 0.51; 95% CI: 0.41

HR 52

HR Trials Medicine Clinical Trials 52

Pharmaceutical Technology

MARCH 2, 2023

Pembrolizumab is under clinical development by Merck and currently in Phase III for Bile Duct Cancer (Cholangiocarcinoma). GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

FDA Approval 100

FDA Approval Containment Development Genome 100

The Pharma Data

NOVEMBER 24, 2020

The safety and efficacy of Oxlumo are also being evaluated in the ongoing ILLUMINATE-C Phase 3 clinical trial in patients of all ages with advanced PH1, including patients on dialysis. 0.514 mmol/24 hr/1.73 0.771 mmol/24 hr/1.73 Visit OXLUMO.com for more information, including full Prescribing Information.

FDA Approval 52

FDA Approval Production RNA Medicine 52

The Pharma Data

AUGUST 9, 2021

The safety profile of Enhertu was consistent with previous clinical trials, with no new safety concerns identified and no Grade 4 or 5 treatment-related interstitial lung disease events. The data will be presented at an upcoming medical meeting and shared with health authorities.

Trials 52

Trials Medicine Development Clinical Trials 52

The Pharma Data

APRIL 11, 2021

Patients treated with this combination had a decrease in risk of disease progression or death by 48% (HR=0.52, p=0.000002) compared to patients treated with placebo and rituximab, with a median PFS of 21.5 months versus 13.8

HR 52

HR Trials Containment Development 52